Liang Huang

24PUBLICATIONS
98CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Tissue engineeringApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Aug 28, 2026
Hematological Malignancy Trials in Chinese Mainland, 2013-2022: A Landscape Analysis with Exploratory Macro-Level Temporal Correlations.

|Jul 22, 2026
Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.

|Jun 27, 2026
Bispecific antibody engineered extracellular vesicles redirect T cells to prevent postoperative epidural fibrosis.

|May 29, 2026
Unraveling cellular and molecular mechanisms of relapse in CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia.

|Feb 07, 2026
Engineered extracellular vesicles displaying bi-specific T-cell engagers for targeted therapy of B-cell malignancies.

Xiuxiu Yang, Qian Xu, Jue Wang

|Nov 30, 2025
CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity.

Jia Wu, Jiali Cheng, Li Zhu

Pageof 4

Frequent Collaborators

6 joint publications

Chunrui Li

4 joint publications

Jianfeng Zhou

3 joint publications

Min Xiao

3 joint publications

Wen Wang